A ‘cure’ for haemophilia is one step closer, following results of a groundbreaking gene therapy trial led by the NHS in London.
Clinical researchers at Barts Health NHS Trust and Queen Mary University of London have found that over one year on from a single treatment with a gene therapy drug, participants with haemophilia A (the most common type) are showing normal levels of the previously missing protein, and effectively curing them.
A single infusion of the gene therapy drug showed improved levels of the essential blood clotting protein Factor VIII, with 85 per cent of patients achieving normal or near-normal Factor VIII levels even many months after treatment.
The ‘transformational’ results have particular significance as the first successful gene therapy trial for the haemophilia A.
A hereditary genetic condition
There are around 2000 people with severe haemophilia A in the UK. A hereditary genetic condition dominantly affecting men, people with severe haemophilia A have virtually none of the protein factor VIII which is essential for blood to clot. It puts those affected at risk of excessive bleeding even from the slightest injury as well as causing spontaneous internal bleeding, which can be life-threatening. Recurring bleeding into joints can also lead to progressive joint damage and arthritis. The only current treatment involves multiple weekly injections to control and prevent bleeding, but there is no cure.
The trial saw patients across England injected with a copy of the missing gene, which allows their cells to produce the missing clotting factor. Following patients for up to nineteen months, tests show that eleven out of thirteen patients in the trial now have normal or near normal levels of the previously missing factor and all thirteen patients have been able to stop their previously regular treatment.
Professor John Pasi, Haemophilia Centre Director at Barts Health NHS Trust and Professor of Haemostasis and Thrombosis at Queen Mary University of London explained: “We have seen mind-blowing results which have far exceeded our expectations. When we started out we thought it would be a huge achievement to show a five per cent improvement, so to actually be seeing normal or near normal factor levels with dramatic reduction in bleeding is quite simply amazing. We really now have the potential to transform care for people with haemophilia using a single treatment for people who at the moment must inject themselves as often as every other day. It is so exciting.”
The team will now hold further tests widening participants globally to include people in the USA, Europe, Africa and South America.
Professor Pasi continued: “Incredibly exciting is the potential for a significant change in how haemophilia is treated globally. A single dose of medication that can so dramatically improve the lives of patients across the world is an amazing prospect.”
Professor Jo Martin, President, The Royal College of Pathologists said: “Pathology research is often responsible for ground-breaking developments in diagnoses and treatments that transform the lives of patients.
“What is truly remarkable about this revolutionary new gene therapy are the profound life-changing effects it offers patients with haemophilia. We would like to congratulate College fellow, Professor Pasi, and his team at Barts Health NHS Trust and Queen Mary University of London for their work in creating a simple but transformational treatment for patients.”
Case study
Jake Omer, 29 lives in Billericay and is married with two children, aged 3 years and a baby of 5 weeks. Diagnosed at two years old, he has had frequent injections of factor VIII to prevent bleeds ever since. Before he was treated with the gene therapy, Jake would wake up early before work to inject three times a week as well as injecting whenever he had an injury to stop the bleeding. As a result of of repeated bleeding Jake has arthritis in his ankles. His father is a Turk-Cypriot and as a child he and his family could never travel to visit relatives in case he needed medical care as the facilities wouldn’t have been available.
Jake said: “The gene therapy has changed my life. I now have hope for my future. It is incredible to now hope that I can play with my kids, kick a ball around and climb trees well into my kids’ teenage years and beyond. The arthritis in my ankles meant I used to worry how far I would be able to walk once I turned 40. At 23 I struggled to run 100m to catch a bus; now at 29 I’m walking two miles every day which I just couldn’t have done before having the gene therapy treatment.
“It’s really strange to not have to worry about bleeding or swellings. The first time I noticed a difference was about four months after the treatment when I dropped a weight in the gym, bashing my elbow really badly. I started to panic thinking this is going to be really bad, but after icing it that night I woke up and it looked normal. That was the moment I saw proof and knew that the gene therapy had worked.”
Learn more: Groundbreaking gene therapy trial set to cure haemophilia
The Latest on: Haemophilia
[google_news title=”” keyword=”haemophilia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Pharmaceutical giants knowingly sold HIV-infected treatment to NHSon May 4, 2024 at 11:59 am
Pharmaceutical companies knowingly sold a treatment infected with HIV to the NHS, The Telegraph can reveal. Internal documents from American pharmaceutical companies show they knew a “wonder drug” ...
- What is the infected blood scandal about?on May 3, 2024 at 11:00 pm
The infected blood scandal saw thousands of people in the UK in the 70s and 80s given blood transfusions or blood products that were infected with viruses such as Hepatitis B, Hepatitis C and HIV.
- Infected blood survivors should receive compensation before families of those who died, says peeron May 3, 2024 at 7:20 am
Jeremy Hunt must speed up compensation payments to survivors of the infected blood scandal, a peer whose husband was killed by the treatment disaster has said. Baroness Campbell of Surbiton has urged ...
- Pfizer’s one-time haemophilia B therapy Beqvez granted FDA approvalon April 30, 2024 at 4:27 am
Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderate-to-severe haemophilia B.
- Pfizer receives FDA approval for haemophilia B gene therapyon April 29, 2024 at 4:29 am
Pfizer has received approval from the US Food and Drug Administration (FDA) for its one-time gene therapy BEQVEZ for haemophilia B.
- Pfizer offers warranty for new haemophilia B therapy Beqvezon April 29, 2024 at 12:24 am
Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting a price directly in line ...
- Haemophilia: Unveiling the bleeding diseaseon April 28, 2024 at 5:00 pm
Haemophilia, a rare genetic blood disorder primarily affecting males, is a non-communicable disease (NCD) with global implications. According to the World Federation of Hemophilia (WFH), of the ...
- Doctors who treated patients with infected blood worked for firms making iton April 27, 2024 at 8:31 am
Doctors who treated patients with infected blood products worked for the companies who made them, The Telegraph can disclose.
- Doctors ‘bribed to use infected blood products’on April 26, 2024 at 1:00 pm
Pharmaceutical giants have been accused of bribing doctors to use infected blood products that gave patients HIV and hepatitis C.
- Haemophilia in children: what parents need to knowon April 23, 2024 at 6:57 am
As the global community observed World Haemophilia Day on April 17, under the theme “Equitable access for all: recognising all bleeding disorders”, the Gauteng Department of Health wishes to educate ...
via Google News and Bing News